A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer

Taira, Yoichi; Shimoji, Yuko; Nakasone, Tadaharu; Arakaki, Yoshio; Nakamoto, Tomoko; Kudaka, Wataru; Aoki, Yoichi

doi:10.1111/jog.14589

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A literature search of PubMed found few case reports published of septum perforation with bevacizumab [7][8][9][10][11][12][13][14][15][16]. The scientific literature regarding the incidence of this complication is scarce.…”

Section: Discussionmentioning

confidence: 99%

Perforation of the Nasal Septum in a Colorectal Cancer Patient Treated With Aflibercept: A Case Report

Fuentes¹,

Lorenzo²,

Elías³

et al. 2022

Cureus

View full text Add to dashboard Cite

Aflibercept is an antiangiogenic agent used in patients with metastatic colorectal cancer who have progressed to a first-line oxaliplatin-based regimen. The main adverse effects (AEs) of antiangiogenic agents are fatigue, asthenia, anorexia, hypertension, proteinuria, urinary tract infection, diarrhea, and neutropenia. Other AEs, such as hemorrhage, thromboembolic events, and gastrointestinal perforation, are much less frequent. Nasal septal perforation caused by antiangiogenic agents is even rarer. The published literature on this subject is scarce. Here, we report the case of a 54-year-old male with metastatic colorectal cancer undergoing treatment with leucovorin, fluorouracil (5-FU), irinotecan, and aflibercept who presented with epistaxis and nasal congestion. An otolaryngologist performed a rhinoscopy that revealed a perforation of the nasal septum. Aflibercept was withdrawn first, and local treatment was applied with lubricant and antibacterial lotions. It was considered a non-life-threatening side effect, and given the high risk of not continuing treatment in this patient with a recent recurrence, aflibercept was reintroduced in combination with leucovorin, 5-FU, and irinotecan. The patient continued local treatment and follow-up with medical oncology and otolaryngology with gradual improvement of symptoms. Follow-up was discontinued due to disease progression and death after 16 months of the event.

show abstract

Section: Discussionmentioning

confidence: 99%

Perforation of the Nasal Septum in a Colorectal Cancer Patient Treated With Aflibercept: A Case Report

Fuentes¹,

Lorenzo²,

Elías³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…(1) According to the criteria of Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [ 11 ], the treatment efficiency was classified as complete remission (CR), partial remission (PR), stable disease (SD), and disease progression (PD). The treatment efficiency = CR + PR.…”

Section: Methodsmentioning

confidence: 99%

Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions

Zhao

Cai

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Objective. To evaluate the efficacy of bevacizumab and gemcitabine in combination with cisplatin in the treatment of esophageal cancer and the effect on the incidence of adverse reactions. Methods. A total of 100 esophageal cancer patients admitted to our hospital from March 2019 to March 2021 were identified as research subjects and randomized into the control group and the study group, with 50 cases in each group. The control group was treated with gemcitabine combined with cisplatin, and the study group was treated with the triple therapy of bevacizumab, gemcitabine, and cisplatin. The treatment efficiency and the incidence of adverse reactions were compared between the two groups of patients. Results. The total treatment efficiency in the study group was 86%, which was significantly higher than that of 66% in the control group ( P < 0.05 ). After treatment, the levels of vascular endothelial growth factor (VEGF), Cyfra21-1, and C-met were reduced in both groups, with significantly lower levels in the study group than in the control group ( P < 0.05 ). The incidence of all CTCAE, ototoxicity, and nephrotoxicity was comparable between the two groups ( P > 0.05 ). The survival rates of patients in the study group were 88% and 54% at 1 and 2 years after treatment, which were significantly higher than that of 68% and 32% in the control group ( P < 0.05 ). Conclusion. The clinical efficiency of bevacizumab and gemcitabine combined with cisplatin in the treatment of esophageal cancer is remarkable, which improves the survival of patients, and is worthy of clinical promotion and application.

show abstract

Bevacizumab

2021

Reactions Weekly

View full text Add to dashboard Cite

A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer

Cited by 4 publications

References 21 publications

Perforation of the Nasal Septum in a Colorectal Cancer Patient Treated With Aflibercept: A Case Report

Perforation of the Nasal Septum in a Colorectal Cancer Patient Treated With Aflibercept: A Case Report

Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions

Bevacizumab

Contact Info

Product

Resources

About